Effect of granulocyte-colony stimulating factor on systolic function of oncology patients.
Rafael S
RS
Cires
Harsh
H
Patel
Leonardo J
LJ
Tamariz
Joshua M
JM
Hare
Juan P
JP
Zambrano
D000328:Adult; D000368:Aged; D018943:Anthracyclines / Q000009:adverse effects / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D009202:Cardiomyopathies / Q000139:chemically induced* / Q000000981:diagnostic imaging / Q000517:prevention & control; D054715:Cardiotoxins / Q000009:adverse effects* / Q000627:therapeutic use; D016022:Case-Control Studies; D015150:Echocardiography, Doppler; D005260:Female; D016179:Granulocyte Colony-Stimulating Factor / Q000627:therapeutic use*; D006321:Heart / Q000187:drug effects; D006801:Humans; D008297:Male; D008875:Middle Aged; D009369:Neoplasms / Q000188:drug therapy*; D012016:Reference Values; D012189:Retrospective Studies; D013318:Stroke Volume / Q000187:drug effects; D000068878:Trastuzumab; D016896:Treatment Outcome
D018943:Anthracyclines; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D054715:Cardiotoxins; D016179:Granulocyte Colony-Stimulating Factor; D000068878:Trastuzumab